Market Place
Sourcing Support
Vistagen Reports FY2025 Q2 Financial Results & Updates
07 Nov 2024 //
BUSINESSWIRE
Vistagen to Report FY 2025 Q2 Results on Nov 7, 2024
01 Nov 2024 //
BUSINESSWIRE
Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol
23 Sep 2024 //
BUSINESSWIRE
Vistagen Reports Q1 2025 Results And Corporate Update
13 Aug 2024 //
BUSINESSWIRE
Vistagen Expands PH80 IP For Migraine Treatment
09 Jul 2024 //
BUSINESSWIRE
Vistagen To Report FY2024 Results, Host Call On June 11
07 Jun 2024 //
BUSINESSWIRE
Vistagen to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Vistagen Ascp Psychopharmacology: 2024 Conference Presentation Scheduled
23 May 2024 //
BUSINESSWIRE
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
07 May 2024 //
BUSINESSWIRE
Vistagen`s PH15 Shows Positive Results in Mental Fatigue Phase 2A Study
25 Apr 2024 //
BUSINESSWIRE
Vistagen to Present at 2024 ADAA Conference
09 Apr 2024 //
BUSINESSWIRE
Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder
01 Apr 2024 //
BUSINESSWIRE
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
BUSINESSWIRE
Vistagen Reports Fiscal 2024 Third Quarter Financial Results
13 Feb 2024 //
BUSINESSWIRE
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results
06 Feb 2024 //
BUSINESSWIRE
Vistagen Receives Notice from Patent Office to Grant Patent for AV-101
27 Dec 2023 //
BUSINESSWIRE
Vistagen to Present at Stifel 2023 Healthcare Conference
08 Nov 2023 //
BUSINESSWIRE
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
05 Oct 2023 //
BUSINESSWIRE
Vistagen Announces Pricing of $100 Million Underwritten Offering
02 Oct 2023 //
BUSINESSWIRE
Sorrento goes to China with Covid drug; Vistagen touts data on PMDD nasal spray
13 Sep 2023 //
ENDPTS
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80
12 Sep 2023 //
BUSINESSWIRE
Vistagen Appoints Cindy Anderson as Chief Financial Officer
22 Aug 2023 //
BUSINESSWIRE
Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray
10 Aug 2023 //
PR NEWSWIRE
Vistagen To Report First Quarter Financial Results
08 Aug 2023 //
BUSINESSWIRE
Vistagen stock soars 1,272% on social anxiety spray data
08 Aug 2023 //
FIERCE BIOTECH
Vistagen Announces Positive Results from Phase 3 Trial of Fasedienol
07 Aug 2023 //
BUSINESSWIRE
Vistagen Reports Preclinical Data Supporting Itruvone Nasal Spray’s Potential
17 Jul 2023 //
BUSINESSWIRE
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent
13 Jul 2023 //
BUSINESSWIRE
Vistagen to Announce Fiscal Year 2023 FYR and Provide Corporate Update
27 Jun 2023 //
BUSINESSWIRE
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
23 Jun 2023 //
BUSINESSWIRE
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10)
21 Jun 2023 //
BUSINESSWIRE
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference
16 Jun 2023 //
BUSINESSWIRE
Vistagen Announces European Patent Office Intention to Grant PH80 Patent
13 Jun 2023 //
BUSINESSWIRE
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80
07 Jun 2023 //
BUSINESSWIRE
Vistagen Announces Stockholder-Approved Reverse Stock Split
06 Jun 2023 //
BUSINESSWIRE
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
06 Jun 2023 //
BUSINESSWIRE
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data
01 Jun 2023 //
BUSINESSWIRE
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data
30 May 2023 //
BUSINESSWIRE
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace
24 May 2023 //
BUSINESSWIRE
Vistagen Presents New Fasedienol (PH94B) Research at 2023 A
19 Apr 2023 //
BUSINESSWIRE
Vistagen Receives New European Patent for AV-101
06 Apr 2023 //
BUSINESSWIRE
FDA Provides Positive Feedback to Vistagen Regarding Use of the LSAS
30 Mar 2023 //
BUSINESSWIRE
Vistagen Announces Positive Data in Fasedienol PIII Study for Anxiety Disorder
22 Mar 2023 //
BUSINESSWIRE
VistaGen`s social anxiety nasal spray finds open-label success
22 Mar 2023 //
FIERCE BIOTECH
Vistagen Announces Completion of Last Patient in PI Trial of Itruvone
08 Mar 2023 //
BUSINESSWIRE
Vistagen to Present at Cowen 43rd Annual Health Care Conference
02 Mar 2023 //
BUSINESSWIRE
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray
01 Mar 2023 //
BUSINESSWIRE
Vistagen pauses anxiety trial restart after seeing rivals fail
08 Feb 2023 //
FIERCE BIOTECH
Vistagen Reports Fiscal 2023 Third Quarter Financial Results
07 Feb 2023 //
BUSINESSWIRE
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results
06 Feb 2023 //
BUSINESSWIRE
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
02 Feb 2023 //
BUSINESSWIRE
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10
24 Jan 2023 //
BUSINESSWIRE
Vistagen Announces Completion of Last Patient in Phase 2 Trial of PH94B
10 Jan 2023 //
BUSINESSWIRE
Vistagen Advances IP Program to Expand Patent Protection for PH94B
30 Dec 2022 //
BUSINESSWIRE
Vistagen buys out Pherin more than 4 years after licensing now-lead social anxiety spray
22 Dec 2022 //
FIERCEPHARMA
Vistagen Receives FDA Fast Track Designation for Development of PH10
06 Dec 2022 //
BUSINESSWIRE
Vistagen Receives FDA “Study May Proceed” Letter Under its iNDA for PH10
30 Nov 2022 //
BUSINESSWIRE
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential
17 Nov 2022 //
BUSINESSWIRE
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
10 Nov 2022 //
BUSINESSWIRE
Vistagen to Report Fiscal Year 2023 Q2 Financial Results on November 10, 2022
04 Nov 2022 //
BUSINESSWIRE
